BPC-157 TB-500

Rows are ordered by price per mg: listed price divided by stated peptide content, excluding shipping and codes, so every vial competes on the same axis. Each row carries its own $/mg figure, so the size of the gap between vendors is visible, not just the order. Sprays follow the vials, unranked.

The best-documented testing flag goes to the vendor publishing batch-level, third-party certificates. The shipping flag goes to the fastest published delivery from a domestic warehouse. Data is re-checked on a schedule and each row carries its verification date.

Dual-peptide blend of BPC-157 + TB-500 — the go-to recovery and tissue-repair stack.

BPC-157 is a synthetic 15-amino-acid peptide derived from a gastric protective protein. As of 2026, only 3 published human studies exist (all pilot-scale with <30 subjects), but 500+ preclinical studies show tissue healing effects. A 2025 IV safety study (up to 20mg) in healthy adults showed no adverse events across cardiac, hepatic, and renal biomarkers.

BPC-157 is a synthetic 15-amino-acid pentadecapeptide (gastric peptide fragment). BPC-157 is a synthetic 15-amino-acid peptide derived from a gastric protective protein. As of 2026, only 3 published human studies exist (all pilot-scale with <30 subjects), but 500+ preclinical studies show tissue healing effects. A 2025 IV safety study (up to 20mg) in healthy adults showed no adverse events across cardiac, hepatic, and renal biomarkers. It has a molecular formula C62H98N16O22, mass 1419.53 Da. Its published amino-acid sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Common synonyms in the literature include Body Protection Compound-157, Bepecin, and PL 14736. This SKU is a co-formulated blend that also contains TB-500 (Thymosin Beta-4 Fragment) in the same vial — for research groups that want to combine the two under a single reconstitution.

Investigation of BPC-157 to date is primarily preclinical, with the majority of citations concentrated in animal models and in-vitro assays rather than randomized controlled human trials. Published work referencing BPC-157 spans In-vitro cell culture studies: BPC-157 has been examined in fibroblast, endothelial cell, and smooth muscle cell lines to observe effects on cell migration, proliferation, oxidative stress responses, and signaling pathway activation. These controlled experiments provide mechanistic insight at the cellular level but do not fully represent complex whole-organism physiology, Tendon and ligament models: Rodent studies have investigated BPC-157 in surgically induced or chemically induced tendon injuries, including Achilles tendon transection models. Researchers have reported observations on healing timelines, collagen fiber alignment, tensile strength measurements, and histological markers of tissue maturation, and Musculoskeletal injury research: Animal studies have explored BPC-157 in crushed muscle and transected muscle paradigms, with observations reported on fibroblast survival, cell migration, biomechanical recovery metrics, and regeneration markers. Proposed mechanisms in the literature include VEGF and angiogenesis: upregulates VEGF expression in vivo, activates VEGFR2 receptors on endothelial cells, triggers Akt-eNOS pathway phosphorylation and Nitric oxide modulation: enhances endothelial NOS (eNOS) activity via Src-Cav-1-eNOS pathways, influences NO synthase activity and vascular tone. None of this material describes therapeutic outcomes in humans, and No vendor listed here provides dosing guidance for BPC-157 outside laboratory research.

For the full mechanistic profile, published references, and constraint notes on BPC-157, see the BPC-157 research page. All references cited on that page are peer-reviewed primary literature.